Featured Publications

Guidelines for the use of immunotherapy to treat patients with bladder carcinoma were recently published as part of the Society for Immunotherapy of Cancer’s (SITC) Cancer Immunotherapy Guidelines series. It joins guidelines for prostate carcinoma, hematologic malignances, and renal cell carcinoma as a crucial resource developed through multidisciplinary collaboration between academic researchers and physicians, nurses, patients, and patients advocates from throughout the U.S.

The SITC Combination Immunotherapy Task Force white paper published earlier this year, entitled “Combination immunotherapy: a road map” (Ott et al.), aims to identify the most promising prospects for combination therapy and address challenges associated with combinatorial approaches. Building on previous work on combination immunotherapy, this article is the first to address the use of mouse models, safety considerations in early clinical testing, the need for innovative early phase clinical trial designs, and appropriate safety and efficacy endpoints for early phase clinical trials, all in the specific setting of combination immunotherapy.

Article series

Immune monitoring technology primers
Reviewed by the members of the SITC Immune Biomarkers Task Force, these brief primers highlight important aspects of both standardized and novel technologies available in clinical trial settings.

SITC Cancer immunotherapy guidelines
Developed by experts in the treatment of specific types of cancer, each consensus statement provides key indicators to help practicing oncologists determine when and how to best use immunotherapy to treat their patients.​​​​​​​

Articles

October Articles

RESEARCH ARTICLE

New Content Item

Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression; efficacy and safety of combined treatment

Brain metastases are common in patients with metastatic melanoma. With increasing numbers of melanoma patients on anti-PD-1 therapy, we sought to evaluate the safety and initial response of brain metastases...

Erik S. Anderson, Michael A. Postow, Jedd D. Wolchok, Robert J. Young, Åse Ballangrud, Timothy A. Chan, Yoshiya Yamada and Kathryn Beal

RESEARCH ARTICLE

New Content Item

Objective measurement and clinical significance of IDO1 protein in hormone receptor-positive breast cancer

Immunostimulatory therapies targeting immune-suppressive pathways produce durable responses in advanced solid tumors. Indoleamine 2,3-dioxygenase (IDO) is the rate-limiting oxidoreductase that catalyzes...

Daniel E. Carvajal-Hausdorf, Nikita Mani, Vamsidhar Velcheti, Kurt A. Schalper and David L. Rimm

 

REVIEW

New Content Item

Immuno-thermal ablations – boosting the anticancer immune response

The use of immunomodulation to treat malignancies has seen a recent explosion in interest. The therapeutic appeal of these treatments is far reaching, and many new applications continue to evolve. In...

Ryan Slovak, Johannes M. Ludwig, Scott N. Gettinger, Roy S. Herbst and Hyun S. Kim

REVIEW

New Content Item

The immune system in cancer metastasis: friend or foe?

Metastatic disease is the leading cause of death among cancer patients and involves a complex and inefficient process. Every step of the metastatic process can be rate limiting and is influenced by...

Louise M.E. Janssen, Emma E. Ramsay, Craig D. Logsdon and Willem W. Overwijk

 

View all articles

Aims and scope

Journal for ImmunoTherapy of Cancer (JITC) is an open access, peer reviewed journal that encompasses all aspects of tumor immunology and cancer immunotherapy, from basic research through to clinical applications.

JITC welcomes submissions to the following sections:

Society affiliation

Free Publication for Society Members

As a way to say thank you to the dedicated Society for Immunotherapy of Cancer (SITC) members who tirelessly work to advance the science and ultimately to improve the lives of patients with cancer, the Society is pleased to offer its members waived article processing charges for manuscripts accepted in JITC through 2016.

JITC Best Paper Awards

Awards were presented during SITC’s 31st Annual Meeting to the first authors of two JITC articles, representing the Best Clinical/Translational and Best Basic Science Papers published in JITC. Congratulations to Zipei Feng, Sachin Puri, and Katherine Woods!

For more information please email info@sitcancer.org, call +1 414 271-2456, or visit http://sitcancer.org/journal.

About SITC

The Society for Immunotherapy of Cancer (SITC) is a 501 (c)(3) non-profit society of medical professionals that was established in 1984 to exchange, encourage and promote information about the promise and breakthroughs of biological therapies, including immunotherapy, for patients with cancer. SITC is the world's leading member-driven society of medical professionals dedicated to advancing cancer immunotherapy through its initiatives, educational sessions, and collaborative endeavors. The Society has become the forum for innovative discussions in the field.

Society members include nearly 1000 influential leaders and scientists engaged in tumor immunology and cancer immunotherapy, including academicians, senior researchers, clinicians, students, government representatives, and industry leaders from around the world. SITC's members represent 17 medical specialties and are engaged in research and treatment of at least a dozen types of cancer.

SITC Mission

It is the mission of the Society for Immunotherapy of Cancer to improve cancer patient outcomes by advancing the science, development and application of immunotherapy through our core values of interaction/integration, innovation, translation and leadership in the field. SITC aims to make cancer immunotherapy a standard of care and the word “cure” a reality for cancer patients everywhere.

Advertisement

JITC logo

Advertisement